Alta Advisers’s ResMed RMD Stock Holding History

Alta Advisers’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-500	Closed	-$122K	–	355
2024 Q3	$122K	Hold	500	–	–	0.06%	242
2024 Q2	$95.7K	Hold	500	–	–	0.05%	277
2024 Q1	$99K	Hold	500	–	–	0.05%	281
2023 Q4	$86K	Hold	500	–	–	0.05%	290
2023 Q3	$73.9K	Hold	500	–	–	0.04%	301
2023 Q2	$109K	Hold	500	–	–	0.06%	222
2023 Q1	$109K	Hold	500	–	–	0.07%	208
2022 Q4	$104K	Hold	500	–	–	0.06%	213
2022 Q3	$109K	Buy	+500	New	+$114K	0.07%	186

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Alta Advisers's RMD Position: Q4 2024 in Review

Alta Advisers sold out of ResMed (RMD) in Q4 2024, closing a stake of 500 shares — an estimated $122K sold.

Alta Advisers first reported a position in RMD in Q3 2022 and held it in 9 quarters. The position peaked at $122K in Q3 2024. 871 funds tracked by Wall St. Rank hold RMD as of Q4 2024.

Alta Advisers reported no remaining ResMed position as of Q4 2024 after selling out during the quarter.
Alta Advisers sold 500 ResMed shares in Q4 2024, an estimated $122K.
Alta Advisers first reported a position in ResMed in Q3 2022 and held it in 9 quarters.
Alta Advisers's ResMed position peaked at $122K in Q3 2024.
871 funds tracked by Wall St. Rank held ResMed as of Q4 2024.

Based on Alta Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.